Description

Irucalantide is a synthetic peptide molecule specifically developed as a kallikrein inhibitor, providing precise modulation of proteolytic activity in various biological systems. With a high purity of 99.72%, this compound is ideally suited for scientific laboratories investigating kinin–kallikrein pathways, inflammatory cascades, and cardiovascular regulation.

The compound’s mechanism centers on the suppression of plasma kallikrein activity, which is a key regulator of the kinin–bradykinin axis. Dysregulation of this pathway has been linked to a wide range of conditions, including hereditary angioedema (HAE), inflammation-related disorders, and vascular permeability dysfunction.

Research interest in Irucalantide also extends to renal biology, cardiovascular physiology, and immunology, where modulation of kallikrein activity provides insight into novel therapeutic approaches.

Manufactured under GMP-compliant conditions, Irucalantide ensures consistent quality, reproducibility, and traceability for laboratory research projects. It is offered in both bulk and smaller quantities, making it suitable for academic, preclinical, and pharmaceutical studies.

Product Specifications

Mechanism of Action & Research Applications

Irucalantide functions as a direct inhibitor of kallikrein, a serine protease involved in the conversion of kininogen to bradykinin. By blocking this enzymatic step, Irucalantide helps reduce excessive bradykinin formation, which is known to cause inflammation, vasodilation, and increased vascular permeability.

Key areas of research include:

• Inflammation Studies: Investigating bradykinin-mediated signaling in chronic inflammatory conditions.

• Cardiovascular Research: Exploring the role of kallikrein in blood pressure regulation, vascular tone, and endothelial permeability.

• Hereditary Angioedema Models: Evaluating kallikrein inhibition as a therapeutic strategy to reduce angioedema attacks.

• Protease Regulation: Studying protease–inhibitor balance within the broader serine protease cascade.

• Renal Research: Assessing the kallikrein–kinin system’s involvement in kidney function and salt homeostasis.

Through these diverse applications, Irucalantide offers researchers a versatile tool for exploring disease pathways and developing potential new therapies.

Development & Research Background

The study of kallikrein inhibitors has grown significantly due to the central role of the kinin–kallikrein system in inflammation and vascular biology. Irucalantide, as a synthetic peptide inhibitor, represents a new class of molecules designed for improved stability and selectivity.

Research on kallikrein has revealed its dual involvement in both normal physiological processes (such as blood flow and renal salt balance) and pathological states (such as angioedema, inflammatory disorders, and cardiovascular dysfunction). By offering a precise tool to block kallikrein activity, Irucalantide provides researchers with the ability to dissect complex biochemical pathways.

Its development has been supported by studies showing that selective inhibition of kallikrein may reduce vascular leakage, tissue swelling, and inflammatory response, while maintaining critical systemic functions. This balance makes Irucalantide a valuable compound for preclinical models of disease and translational research efforts.

Side Effects

In laboratory models, potential side effects of kallikrein inhibition include:

• Altered vascular tone and blood pressure regulation

• Reduced bradykinin-mediated vasodilation

• Possible impairment of protective inflammatory responses

• Modulation of renal salt handling

These findings are research observations only and not indicative of safety or efficacy in humans.

Disclaimer

Irucalantide is supplied strictly for laboratory research use only. It is not approved for human or veterinary use, medical treatment, or diagnostic procedures. Handling should only be conducted by trained professionals in a laboratory environment.

Keywords

Irucalantide, CAS 1631160-47-8, kallikrein inhibitor, bradykinin pathway research, inflammation research peptide, hereditary angioedema research, GMP peptide supplier, high purity peptide inhibitor, protease regulation studies, cardiovascular research compound